Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on ...

After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...

Quantitative CT in AATD linked airway wall thickening and bronchiectasis to lung function, while wall thickness best ...

Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.

The U.S. FDA has cleared Tessera Therapeutics Inc.’s IND application for TSRA-196, its lead in vivo gene editing therapy for α-1 antitrypsin deficiency (AATD). The Australian Human Research Ethics ...

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

Austin, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Market Size & Growth Analysis: According to SNS Insider, The Alpha-1 Antitrypsin Deficiency Market was valued at USD ...

Beam stock launched Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, BEAM-302.

On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with ...

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program ...

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...